CD72 is a pan-tumor antigen associated to pediatric acute leukemia.
acute lymphoblastic leukemia
acute myeloid leukemia
immunophenotyping
Journal
Cytometry. Part A : the journal of the International Society for Analytical Cytology
ISSN: 1552-4930
Titre abrégé: Cytometry A
Pays: United States
ID NLM: 101235694
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
30
08
2023
received:
14
06
2023
accepted:
04
09
2023
pubmed:
25
10
2023
medline:
25
10
2023
entrez:
25
10
2023
Statut:
ppublish
Résumé
In the development of novel immunotherapeutic approaches, the step of target identification is a challenging process, because it aims at identifying robust tumor-associated antigens (TAAs) specific for the pathological population and causing no off-target effects. Here we propose CD72 as a novel and robust TAA for pediatric acute leukemias. We provided an outline of CD72 expression assessed by flow cytometry on a variety of cancer cell lines and primary samples, including normal bone marrow (BM) samples and hematopoietic stem and progenitor cells. We analyzed CD 72 expression on a cohort of 495 pathological pediatric BM aspirates, including: 215 B-cell precursor acute lymphoblastic leukemias (BCP-ALL), 156 acute myeloid leukemias (AMLs), 88 T-lineage ALLs or lymphoblastic lymphomas with BM infiltration, 13 B-lineage lymphoblastic lymphomas with BM infiltration, 9 myelodysplastic syndromes with increased blasts (5%-9% blasts on BM: MDS-IB1) and 14 non-hematopoietic solid tumors infiltrating BM. Results showed that CD72 is highly expressed in almost all BCP-ALL and the majority of AML at diagnosis, including BCP-ALL cases characterized by CD19 loss. These findings support a potential role for advanced diagnostics and novel immunotherapy approaches, providing a pan-ALL and AML target.
Identifiants
pubmed: 37876342
doi: 10.1002/cyto.a.24790
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1004-1009Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro-IG20562
Organisme : Fondazione CARIPARO
Organisme : Synergy grant from Fondazione Istituto di Ricerca Pediatrica-IRP
Organisme : AIL-TV
Informations de copyright
© 2023 The Authors. Cytometry Part A published by Wiley Periodicals LLC on behalf of International Society for Advancement of Cytometry.
Références
Pearson AD, Rossig C, Mackall C, Shah NN, Baruchel A, Reaman G, et al. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer. 2022;160:112-133. Available from: https://pubmed.ncbi.nlm.nih.gov/34840026/
Majzner RG, Mackall CL. Tumor antigen escape from car t-cell therapy. Cancer Discov. 2018;8:1219-1226.
Zheng M, Xing C, Xiao H, Ma N, Wang X, Han G, et al. Interaction of CD5 and CD72 is involved in regulatory T and B cell homeostasis. Immunol Invest. 2014;43:705-716.
Suzuki K, Kumanogoh A, Kikutani H. Semaphorins and their receptors in immune cell interactions. Nat Immunol. 2008;9:17-23. Available from: https://www.nature.com/articles/ni1553. Accessed 14 July 2023
Nix MA, Mandal K, Geng H, Paranjape N, Lin YHT, Rivera JM, et al. Surface proteomics reveals CD72 as a target for In vitro-evolved Nanobody-based CAR-T cells in KMT2A/MLL1-rearranged B-ALL. Cancer Discov. 2021;11:2032-2049.
Swerdlow SH, Campo E, Pileri SA, Lee Harris N, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375-2390.
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57:289-300.
Bausch-Fluck D, Hofmann A, Bock T, Frei AP, Cerciello F, Jacobs A, et al. A mass spectrometric-derived cell surface protein atlas. PLoS One. 2015;10:e0121314.
Basso G, Buldini B, De Zen L, Orfao A. New methodologic approaches for immunophenotyping acute leukemias. Haematologica. 2001;86:675-692.
Dworzak MN, Buldini B, Gaipa G, Ratei R, Hrusak O, Luria D, et al. AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of pediatric acute lymphoblastic leukemia. Cytometry B Clin Cytom. 2018;94:82-93.
Dworzak MN, Gaipa G, Ratel R, Veltroni M, Schumich A, Maglia O, et al. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: multicentric assessment is feasible. Cytom Part B Clinc Cytom. 2008;74B:331-340.
Tregnago C, Manara E, Zampini M, Bisio V, Borga C, Bresolin S, et al. CREB engages C/EBPδ to initiate leukemogenesis. Leukemia. 2016;30:1-10.
Lee JK, Bangayan NJ, Chai T, Smith BA, Pariva TE, Yun S, et al. Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proc Natl Acad Sci U S A. 2018;115:E4473-E4482.
Perna F, Berman SH, Soni RK, Mansilla-Soto J, Eyquem J, Hamieh M, et al. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell. 2017;32:506-519.e5.
Karawajew L, Dworzak M, Ratei R, Rhein P, Gaipa G, Buldini B, et al. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia. Haematologica. 2015;100:935-944.
Maurer-Granofszky M, Schumich A, Buldini B, Gaipa G, Kappelmayer J, Mejstrikova E, et al. An extensive quality control and quality assurance (QC/QA) program significantly improves inter-laboratory concordance rates of flow-cytometric minimal residual disease assessment in acute lymphoblastic leukemia: an I-BFM-FLOW-network report. Cancers (Basel). 2021;13:6148.
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703-1719.
Tembhare PR, Ghogale S, Ghatwai N, Badrinath Y, Kunder N, Patkar NV, et al. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000. Cytom Part B Clin Cytom. 2018;94:100-111.
Von Euw E, Taschereau E, Ou DM, Mead M, Larson S, Slamon D. Abstract 3041: CD72 as a potential new therapeutic target in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Cancer Res. 2019;79:3041.
Bisio V, Zampini M, Tregnago C, Manara E, Salsi V, Di Meglio A, et al. NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group. Leukemia. 2017;31:974-977.
Pigazzi M, Manara E, Bisio V, Aveic S, Masetti R, Menna G, et al. Screening of novel genetic aberrations in pediatric acute myeloid leukemia: a report from the AIEOP AML-2002 study group. Blood. 2012;120:3860-3862.
Pigazzi M, Masetti R, Bresolin S, Beghin A, Di Meglio A, Gelain S, et al. MLL partner genes drive distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an AIEOP study. Leukemia. 2011;25:560-563.
Ghodke K, Bibi A, Rabade N, Patkar N, Subramanian PG, Kadam PA, et al. CD19 negative precursor B acute lymphoblastic leukemia (B-ALL)-Immunophenotypic challenges in diagnosis and monitoring: a study of three cases. Cytometry B Clin Cytom. 2017;92:315-318.
Mikhailova E, Roumiantseva J, Illarionova O, Lagoyko S, Miakova N, Zerkalenkova E, et al. Strong expansion of normal CD19-negative B-cell precursors after the use of blinatumomab in the first-line therapy of acute lymphoblastic leukaemia in children. Br J Haematol. 2022;196:e6-e9.